Comment on "The effect of omalizumab on hematological and inflammatory parameters in patients with chronic spontaneous urticarial": reply from authors.
Ersoy AcerHilal Kaya ErdoganNihan Yüksel ÇanakçıZeynep Nurhan SaracoğluPublished in: Cutaneous and ocular toxicology (2020)
We read Cosansu's commentary entitled "Effectiveness of the new inflammatory parameters in patients with chronic spontaneous urticarial" to our study with great interest. The author remarked that a limited number of patients had C-reactive protein levels and it was not specified whether there were any other drugs used by the patients and no information was given about the severity of the disease in our study.